Table 1.
Baseline characteristics of patients without osteoporosis according to the thyroid-stimulating hormone (TSH) suppression.
| TSH Suppression (−) | TSH Suppression (+) | p-Value | |
|---|---|---|---|
| n | 81 | 83 | |
| Age (years) | 56.6 ± 6.6 | 56.6 ± 6.3 | 0.986 |
| BMI (kg/m2) | 23.8 ± 2.7 | 24.6 ± 3.7 | 0.141 |
| Cancer type: PTC, n (%) | 79 (97.5) | 82 (98.8) | 0.546 |
| TNM stage, n (%) | 0.143 | ||
| Stage I | 60 (74.1) | 50 (60.2) | |
| Stage II | 15 (18.5) | 21 (25.3) | |
| Stage III | 6 (7.4) | 12 (14.5) | |
| Extent of surgery: Total thyroidectomy, n (%) |
64 (79.0) | 77 (92.8) | 0.011 |
| RAI therapy, n (%) | 30 (37.0) | 48 (42.2) | |
| Cumulative dose of RAI (mCi) | 68.3 ± 20.2 | 83.6 ± 36.0 | 0.044 |
| a Mean TSH (mIU/L) | 2.07 ± 1.15 | 0.46 ± 0.32 | 0.000 |
| Laboratory test at the time of diagnosis (pre-operative time) | |||
| TSH (mIU/L) | 1.86 ± 1.04 | 1.97 ± 1.66 | 0.606 |
| Free T4 (ng/dL) | 1.20 ± 0.23 | 1.17 ± 0.31 | 0.523 |
| Calcium (mg/dL) | 9.25 ± 0.41 | 9.14 ± 0.42 | 0.113 |
| Phosphate (mg/dL) | 3.81 ± 0.55 | 3.73 ± 0.46 | 0.300 |
| ALP (IU/L) | 62.80 ± 15.90 | 66.86 ± 22.81 | 0.190 |
| 25OHD (ng/mL) | 18.06 ± 9.37 | 18.54 ± 9.69 | 0.829 |
| iPTH (pg/mL) | 35.34 ± 20.95 | 39.68 ± 28.23 | 0.298 |
a Mean TSH, the integral value of TSH over time divided by the total follow-up period. Values are presented as mean ± standard deviation for continuous variables. Comparisons between the two groups were made using the parametric Student t-test. Abbreviations: PTC, papillary thyroid carcinoma; RAI, radioactive iodine; BMI, body mass index; 25OHD, 25-hydroxy vitamin D3; iPTH, intact PTH; ALP, alkaline phosphatase.